Search results
Results from the WOW.Com Content Network
Nivolumab, sold under the brand name Opdivo, is an anti-cancer medication used to treat a number of types of cancer. [2] This includes melanoma, lung cancer, malignant pleural mesothelioma, renal cell carcinoma, Hodgkin lymphoma, head and neck cancer, urothelial carcinoma, colon cancer, esophageal squamous cell carcinoma, liver cancer, gastric cancer, and esophageal or gastroesophageal ...
In December 2014, the company received FDA approval for the use of the PD-1 inhibitor nivolumab (Opdivo) in treating patients whose skin cancer cannot be removed or have not responded to previous drug therapies. [47] In February 2015, the company initiated a research partnership with Rigel Pharmaceuticals which could generate more than $339 ...
Avelumab is FDA approved for the treatment of metastatic merkel-cell carcinoma. It failed phase III clinical trials for gastric cancer. [33] Durvalumab (Imfinzi) is a fully human IgG1 antibody developed by AstraZeneca. Durvalumab is FDA approved for the treatment of urothelial carcinoma and unresectable non-small cell lung cancer after ...
The FDA has accepted for review Bristol-Myers Squibb Co's (NYSE: BMY) supplemental application for Opdivo (nivolumab) plus chemotherapy for resectable non-small cell lung cancer (NSCLC) in a ...
The FDA said on Wednesday that the approval allows the use of the drug to treat patients with ROS1-positive non-small cell lung cancer (NSCLC), which occurs w US FDA approves Bristol-Myers' lung ...
Exelixis (EXEL) obtains FDA approval for Cabometyx in combination with immuno-oncology drug, Opdivo, for the first-line treatment of patients with advanced kidney cancer.
This list of over 500 monoclonal antibodies includes approved and investigational drugs as well as drugs that have been withdrawn from market; consequently, the column Use does not necessarily indicate clinical usage. See the list of FDA-approved therapeutic monoclonal antibodies in the monoclonal antibody therapy page.
For premium support please call: 800-290-4726 more ways to reach us